Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Medical Treatment in Early COVID-19 Infection
NCT05049213Phase 4Completed
- Sponsor
- National Taiwan University Hospital
- Start
- Jun 2022
- Primary completion
- Aug 2022
- Modality
- Polymer-based Nanoparticles, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of Iota-carrageenan and IVIEW-1502 in coronavirus disease 2019 (COVID-19), sponsored by National Taiwan University Hospital. Primary endpoint: Change from baseline naso-pharyngeal viral load quantified by RT-PCR at Day 8. Started Jun 2022; status: completed.
02
Drugs
Iota-carrageenanIVIEW-1502
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05049213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05049213.